FERMT2 and breast carcinoma: TGF-β1 signaling is elevated in anoikis-resistant breast cancer cells [18], and FERMT2 knockdown reduces TβRI expression [19], suggesting FERMT2 may regulate AR through the TGF-β1 pathway.